Prognostic Role of Beta‐2 Microglobulin in Diffuse Large B‐Cell Lymphoma: Systematic Review and Meta‐Analysis of Observational Studies
Cancer Reports · 2025
DOI: 10.1002/cnr2.70416 ↗Kurz gefasst
Systematische Übersicht in der Zeitschrift Cancer Reports, 2025. Verfasst von Hamideh Feiz Disfani und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Emergency Medicine, School of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran. Hauptthemen laut MEDLINE: Lymphoma, Large B-Cell, Diffuse, beta 2-Microglobulin, Biomarkers, Tumor. Die Arbeit nennt 63 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Background
Evidence indicates that beta‐2 microglobulin (β2M) plays a prognostic role in patients with diffuse large B‐cell lymphoma (DLBCL).
Aim
However, due to controversies among previous studies, this meta‐analysis was conducted to evaluate the prognostic role of β2M in DLBCL patients. Methods and Results Relevant studies were identified through a systematic search using specific keywords in PubMed/Medline, Scopus, and Web of Science databases. Studies that provided complete information on the hazard ratio with a 95% confidence interval for β2M with respect to overall survival (OS) and progression‐free survival (PFS) in multivariate models were included in the meta‐analysis. A total of 30 studies, encompassing 25 128 patients, were included in this meta‐analysis. The pooled analysis demonstrated a significant association between elevated β2M levels and poor OS in DLBCL patients (HR Pooled : 1.65, 95% CI: 1.45–1.88, p ‐value < 0.01). Similarly, increased β2M levels were significantly associated with lower PFS in DLBCL patients (HR Pooled : 1.54, 95% CI: 1.39–1.70, p ‐value < 0.01).
Conclusion
The available evidence suggests that β2M serves as an independent prognostic marker with significant effects on OS and PFS in DLBCL patients. Elevated serum β2M levels are associated with poor prognosis and worse OS and PFS outcomes in DLBCL patients.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Emergency Medicine, School of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran.
- Department of Emergency Medicine, School of Medicine, Neyshabur University of Medical Sciences, Neyshabur, Iran.
- Nano Drug Delivery Research Center, Health Technology Institute, Kermanshah University of Medical Sciences, Kermanshah, Iran.
- Department of Medical Physics, School of Medicine, Iran University of Medical Sciences, Tehran, Iran.
- Hematologist-Oncologist, Department of Internal Medicine, Faculty of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran.
- Department of Emergency Medicine, Faculty of Medicine, Birgand University of Medical Sciences, Birjand, Iran.
ORCID-Profile: Hamideh Feiz Disfani, Mahsan Ramezani, Milad Moradi, Mostafa Kamandi, Molood Foogerdi, Vajiheh Sadat Saghi, Rasoul Shavaleh, Kazem Rahmani
Zitieren
APA
Disfani, H. F., Ramezani, M., Moradi, M., Kamandi, M., Foogerdi, M., Saghi, V. S., Shavaleh, R., & Rahmani, K. (2025). Prognostic Role of Beta‐2 Microglobulin in Diffuse Large B‐Cell Lymphoma: Systematic Review and Meta‐Analysis of Observational Studies. Cancer Reports. https://doi.org/10.1002/cnr2.70416
Vancouver
Disfani HF, Ramezani M, Moradi M, Kamandi M, Foogerdi M, Saghi VS, et al. Prognostic Role of Beta‐2 Microglobulin in Diffuse Large B‐Cell Lymphoma: Systematic Review and Meta‐Analysis of Observational Studies. Cancer Reports. 2025. doi:10.1002/cnr2.70416
BibTeX
@article{Disfani2025,
author = {Disfani, Hamideh Feiz and Ramezani, Mahsan and Moradi, Milad and Kamandi, Mostafa and Foogerdi, Molood and Saghi, Vajiheh Sadat and Shavaleh, Rasoul and Rahmani, Kazem},
title = {Prognostic Role of Beta‐2 Microglobulin in Diffuse Large B‐Cell Lymphoma: Systematic Review and Meta‐Analysis of Observational Studies},
journal = {Cancer Reports},
year = {2025},
doi = {10.1002/cnr2.70416}
}
EUVIMED